At CanaQuest Medical Corp we are currently developing a unique pharmaceutical and health product that utilizes cannabis, hemp, and algae oils. We have a number of patentable product formulations developed and have secured strategic partnership agreements with a number of Canadian and International Licensed Producers providing low cost supply, processing, and international distribution. Our strategic partners enable our company to focus on the product formulations without the need to deploy extensive capital on infrastructure.


Our vision is to be a global leader in the formulation and development of health products from cannabis derivatives.


Utilizing university-level research we have created specific cannabis oil lines.

Western University has performed research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety, and schizophrenia.

Dr. Steven Laviolette, BSc, PhD
Addiction Research Group
Dept. of Anatomy & Cell Biology. Dept. of Psychiatry
Canadian Institute for Military and Veterans Health Research

Dr. Laviolette’s investigations have focused on nicotine and opiates, highly addictive substances that act on pathways in the brain that control reward, motivation and learning. His research group has characterized and identified specific regions in the mammalian brain that control the ‘switch’ from the non-addicted state, to the addicted state following exposure to drugs of abuse. The goal of his research is to determine how specific cannabis-derived phytochemical compounds such as delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD) and other phytochemical and/or terpenoid compounds derived from cannabis, may serve to ameliorate symptoms and/or serve as potential pharmacotherapies for schizophrenia, anxiety, depression and post-traumatic stress disorder.

Dr. Steven Laviolette

The University of Waterloo has performed research and product development on cannabis oil and its constituents in the context of development and treatment of cancers of the colorectum, pancreas, breast and prostate.

Dr. Jonathan Blay, PhD, FRSB, FIBMS, Csci, Cbiol
Professor of Pharmacy, University of Waterloo
Professor of Pathology, Dalhousie University

Dr. Blay’s research group applies a range of techniques in molecular and cellular biology to understand cell behaviour and how the action of existing anticancer drugs are affected by the unique physiology of the cancer. The goal is to perform fundamental cancer-related research on botanical oils and their constituents which will carry out studies relating to the cellular safety and known cancer-related potential of components within the oils.

Dr. Jonathan Blay

CanaQuest Medical Corp will retain the rights of all patents developed in collaboration with universities.